Garcos Pharmaceuticals SHP2 inhibitors are eligible for FDA orphan drugs

According to the press release, JAB-3312 is a SHP2 phosphatase inhibitor (Protein tyrosine phosphatase inhibitor, PTPi), which blocks kras-MAPK signaling pathlines and also relieves the tumor immunosuppressive microenvironment and enhances the effectiveness of existing tumor immunotherapy.
, JAB-3312 has been approved for clinical trials in China and the United States, and the project has been launched in several hospitals in the United States and China.
public information shows that JAB-3312 will be used to treat patients with genotype abnormalities such as KRAS G12 mutations, BRAF Class3, NF1LoF, and RTK mutations, amplification or rearm, including but not limited to non-small cell lung cancer, colorectal cancer, pancreatic cancer, esophageal squamous cancer, head and neck squamous cancer.
at the same time JAB-3312 single drug or combined PD-1 antibody, can also be used by PD-1/PD-L1 antibody treatment failure or drug resistance of non-small cell lung cancer, colorectal cancer, bladder cancer, triple negative breast cancer patients.
it's worth noting that in June, Garcos Pharmaceuticals and AbbVie announced a global strategic partnership to jointly develop and commercialize SHP2 inhibitors that act on key targets for cancer cells and immune cells.
the agreement, AbbVie will be granted exclusive license to Garcos Pharmaceuticals' SHP2 program.
addition to THE JAB-3312, garcos Pharmaceuticals' SHP2 program has another product, JAB-3068.
, JAB-3068 has both tumor immunity and targeted treatment mechanisms, according to publicly available data.
currently, Garcos Pharmaceuticals is evaluating the clinical efficacy of JAB-3068 for three types of solid tumors in Clinical Phase 2a in China.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
the company's laboratory platform has the development of protein phosphatase, KRAS and other transcription factors of the variant inhibitor technology.
, Garcos Pharmaceuticals has received investments from several biotechnology professional investment institutions, including Qiming Ventures, Lilly Asia Fund, Sogo Capital and Taiwan Jade.
addition, Garcos Pharmaceuticals recently filed an IPO application on the Hong Kong Stock Exchange, the company intends to use about 88.0% of the proceeds of the IPO to focus on the clinical development and commercialization of research products.
References: (1) Garcos JAB-3312 is eligible for FDA orphan drugs. Retrieved Oct 20, 2020, from #rd Source: Supplied